The Medical Letter on Drugs and Therapeutics
Three New Drugs for Multiple Myeloma (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA recently approved ixazomib (Ninlaro – Takeda), daratumumab (Darzalex – Janssen Biotech), and elotuzumab (Empliciti – BMS) for treatment of relapsed and/or refractory multiple myeloma.

STANDARD TREATMENT — Use of drug regimens that include the proteasome inhibitor bortezomib (Velcade) plus either the immunomodulating drug thalidomide (Thalomid) or lenalidomide (Revlimid), a thalidomide analog, instead of chemotherapy has led to improved response rates and survival in patients with multiple myeloma.

Carfilzomib (Kyprolis), a second proteasome inhibitor, is an alternative for treatment of refractory multiple myeloma.1 Pomalidomide (Pomalyst), another thalidomide analog, is an alternative for patients with disease progression who have received at least two prior therapies including ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Three New Drugs for Multiple Myeloma (online only)
Article code: 1495d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian